Center-Authored Papers

Filters: Author is Bensinger, William I  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D et al..  2014.  Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S et al..  2012.  Peripheral-blood stem cells versus bone marrow from unrelated donors.. The New England journal of medicine. 367(16):1487-96. Abstract
Anderson KC, Alsina M, Bensinger WI, Biermann SJ, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C et al..  2011.  Multiple myeloma.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(10):1146-83.
Anderson KC, Alsina M, Bensinger WI, Biermann SJ, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA et al..  2009.  NCCN clinical practice guidelines in oncology: multiple myeloma.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(9):908-42.
Anderson KC, Alsina M, Bensinger WI, Biermann SJ, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F et al..  2013.  Multiple Myeloma, Version 1.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(1):11-17. Abstract
Anderson KC, Alsina M, Bensinger WI, Biermann SJ, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F et al..  2012.  Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(10):1211-1219. Abstract
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G et al..  2016.  Carfilzomib significantly improves the progression free survival of high-risk patients in multiple myeloma.. Blood. 128(9):1174-1180. Abstract
B
Baden LR, Bensinger WI, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI et al..  2012.  Prevention and treatment of cancer-related infections.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(11):1412-45. Abstract
Bensinger WI, Schubert MM, Ang K-K, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R et al..  2008.  NCCN Task Force Report. prevention and management of mucositis in cancer care.. Journal of the National Comprehensive Cancer Network : JNCCN. 6 Suppl 1:S1-21;quizS22-4. Abstract
Bensinger WI, Green DJ, Burwick N, Becker PS.  2014.  A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.. Bone marrow transplantation. 49(4):492-5. Abstract
Bensinger WI.  2009.  Role of autologous and allogeneic stem cell transplantation in myeloma.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(3):442-8. Abstract
Bensinger WI, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J et al..  2012.  A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology. :n/a-n/a.
Bensinger WI, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P, Sandmaier BM, Storb R, Maloney D.  2012.  Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center.. Bone marrow transplantation. 47(10):1312-7. Abstract
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH et al..  2010.  Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.. British journal of haematology. 148(4):562-8. Abstract
Bensinger WI.  2012.  Allogeneic transplantation: peripheral blood vs. bone marrow.. Current opinion in oncology. 24(2):191-196. Abstract
Bensinger WI.  2008.  Stem-cell transplantation for multiple myeloma in the era of novel drugs.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(3):480-92. Abstract
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
C
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC et al..  2013.  Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6. Abstract
Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI et al..  2015.  High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.. British journal of haematology. 171(5):788-97. Abstract
Cavo M, Rajkumar VS, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M et al..  2011.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.. Blood. 117(23):6063-73. Abstract
Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD et al..  2015.  Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
D
Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G.  2010.  Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.. Bone marrow transplantation. 45(1):39-47. Abstract
Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales M-A, Cutler CS et al..  2014.  Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines of the American Society for Blood and Marrow Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
G
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger WI, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R et al..  2009.  International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(10):1904-12. Abstract
Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger WI, Copelan E et al..  2013.  Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract